Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2014, Article ID 738679, 8 pages
http://dx.doi.org/10.1155/2014/738679
Research Article

Approach to Reduction of Blood Atherogenicity

1Institute for Atherosclerosis Research, Skolkovo Innovation Center, P.O. Box No. 21, Moscow 121609, Russia
2Institute of General Pathology and Pathophysiology, Baltiyskaya Street 8, Moscow 125315, Russia
3Russian Cardiology Research and Production Center, 3rd Cherepkovskaya Street 15a, Moscow 121552, Russia

Received 14 March 2014; Revised 15 May 2014; Accepted 9 June 2014; Published 29 June 2014

Academic Editor: Carlos Caulin

Copyright © 2014 Alexander N. Orekhov et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. V. Demarin, M. Lisak, S. Morović, and T. Cengić, “Low high-density lipoprotein cholesterol as the possible risk factor for stroke,” Acta Clinica Croatica, vol. 49, no. 4, pp. 429–439, 2010. View at Google Scholar · View at Scopus
  2. P. Libby, P. M. Ridker, and G. K. Hansson, “Progress and challenges in translating the biology of atherosclerosis,” Nature, vol. 473, no. 7347, pp. 317–325, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. P. Maurice, S. Blaise, S. Gayral et al., “Elastin fragmentation and atherosclerosis progression: the elastokine concept,” Trends in Cardiovascular Medicine, vol. 23, no. 6, pp. 211–221, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. P. Fogelstrand and J. Borén, “Retention of atherogenic lipoproteins in the artery wall and its role in atherogenesis,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 22, no. 1, pp. 1–7, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. E. I. Chazov, V. V. Tertov, A. N. Orekhov et al., “Atherogenicity of blood serum from patients with coronary heart disease,” The Lancet, vol. 2, no. 8507, pp. 595–598, 1986. View at Publisher · View at Google Scholar · View at Scopus
  6. A. N. Orekhov, V. V. Tertov, S. N. Pokrovsky et al., “Blood serum atherogenicity associated with coronary atherosclerosis. Evidence for nonlipid factor providing atherogenicity of low-density lipoproteins and an approach to its elimination,” Circulation Research, vol. 62, no. 3, pp. 421–429, 1988. View at Publisher · View at Google Scholar · View at Scopus
  7. A. N. Orekhov, V. V. Tertov, S. A. Kudryashov, and V. N. Smirnov, “Triggerlike stimulation of cholesterol accumulation and DNA and extracellular matrix synthesis induced by atherogenic serum or low density lipoprotein in cultured cells,” Circulation Research, vol. 66, no. 2, pp. 311–320, 1990. View at Publisher · View at Google Scholar · View at Scopus
  8. E. R. Andreeva, I. M. Pugach, and A. N. Orekhov, “Collagen-synthesizing cells in initial and advanced atherosclerotic lesions of human aorta,” Atherosclerosis, vol. 130, no. 1-2, pp. 133–142, 1997. View at Publisher · View at Google Scholar · View at Scopus
  9. E. R. Andreeva, I. M. Pugach, and A. N. Orekhov, “Subendothelial smooth muscle cells of human aorta express macrophage antigen in situ and in vitro,” Atherosclerosis, vol. 135, no. 1, pp. 19–27, 1997. View at Publisher · View at Google Scholar · View at Scopus
  10. P. T. Williams, X. Q. Zhao, S. M. Marcovina, B. G. Brown, and R. M. Krauss, “Levels of cholesterol in small LDL particles predict atherosclerosis progression and incident CHD in the HDL-atherosclerosis treatment study (HATS),” PLoS ONE, vol. 8, no. 2, Article ID e56782, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. T. Yamazaki, R. Nohara, H. Daida et al., “Intensive lipid-lowering therapy for slowing progression as well as inducing regression of atherosclerosis in Japanese patients: subanalysis of the JART study,” International Heart Journal, vol. 54, no. 1, pp. 33–39, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Bambauer, C. J. Olbricht, and E. Schoeppe, “Low-density lipoprotein apheresis for prevention and regression of atherosclerosis: clinical results,” Therapeutic Apheresis, vol. 1, no. 3, pp. 242–248, 1997. View at Publisher · View at Google Scholar · View at Scopus
  13. A. N. Orekhov, V. V. Tertov, A. E. Kabakov, I. Y. Adamova, S. N. Pokrovsky, and V. N. Smirnov, “Autoantibodies against modified low density lipoprotein. Nonlipid factor of blood plasma that stimulates foam cell formation,” Arteriosclerosis and Thrombosis, vol. 11, no. 2, pp. 316–326, 1991. View at Publisher · View at Google Scholar · View at Scopus
  14. V. V. Tertov and A. N. Orekhov, “Metabolism of native and naturally occurring multiple modified low density lipoprotein in smooth muscle cells of human aortic intima,” Experimental and Molecular Pathology, vol. 64, no. 3, pp. 127–145, 1997. View at Publisher · View at Google Scholar · View at Scopus
  15. O. Jaakkola, T. Solakivi, V. V. Tertov, A. N. Orekhov, T. A. Miettinen, and T. Nikkari, “Characteristics of low-density lipoprotein subfractions from patients with coronary artery disease,” Coronary Artery Disease, vol. 4, no. 4, pp. 379–385, 1993. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Loukas, A. Sharma, C. Blaak, E. Sorenson, and A. Mian, “The clinical anatomy of the coronary arteries,” Journal of Cardiovascular Translational Research, vol. 6, no. 2, pp. 197–207, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Hamoud, T. Hayek, N. Volkova et al., “Pomegranate extract (POMx) decreases the atherogenicity of serum and of human monocyte-derived macrophages (HMDM) in simvastatin-treated hypercholesterolemic patients: a double-blinded, placebo-controlled, randomized, prospective pilot study,” Atherosclerosis, vol. 232, no. 1, pp. 204–210, 2014. View at Google Scholar
  18. S. M. Manohar, S. R. Vaikasuvu, K. Deepthi, A. Sachan, and S. R. P. V. L. Narasimha, “An association of hyperglycemia with plasma malondialdehyde and atherogenic lipid risk factors in newly diagnosed type 2 diabetic patients,” Journal of Research in Medical Sciences, vol. 18, no. 2, pp. 89–93, 2013. View at Google Scholar · View at Scopus
  19. N. Beebe, S. Magnanti, L. Katkowski et al., “Effects of the addition of t'ai chi to a dietary weight loss program on lipoprotein atherogenicity in obese older women,” Journal of Alternative and Complementary Medicine, vol. 19, no. 9, pp. 759–766, 2013. View at Publisher · View at Google Scholar
  20. I. A. Sobenin, D. A. Chistiakov, Y. V. Bobryshev, and A. N. Orekhov, “Blood atherogenicity as a target for anti-atherosclerotic therapy,” Current Pharmaceutical Design, vol. 19, no. 33, pp. 5954–5962, 2013. View at Publisher · View at Google Scholar
  21. A. N. Orekhov, I. A. Sobenin, N. V. Korneev et al., “Anti-atherosclerotic therapy based on botanicals,” Recent Patents on Cardiovascular Drug Discovery, vol. 8, no. 1, pp. 56–66, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. I. A. Sobenin, N. V. Korneev, I. V. Romanov et al., “The effects of garlic powder tablets in subclinical carotid atherosclerosis,” Experimental and Clinical Cardiology, vol. 20, no. 1, pp. 629–638, 2014. View at Google Scholar
  23. I. A. Sobenin, L. V. Nedosugova, L. V. Filatova, M. I. Balabolkin, T. V. Gorchakova, and A. N. Orekhov, “Metabolic effects of time-released garlic powder tablets in type 2 diabetes mellitus: the results of double-blinded placebo-controlled study,” Acta Diabetologica, vol. 45, no. 1, pp. 1–6, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. S. E. Akopov, A. N. Orekhov, V. V. Tertov, K. A. Khashimov, E. S. Gabrielyan, and V. N. Smirnov, “Stable analogues of prostacyclin and thromboxane A2 display contradictory influences on atherosclerotic properties of cells cultured from human aorta. The effect of calcium antagonists,” Atherosclerosis, vol. 72, no. 2-3, pp. 245–248, 1988. View at Publisher · View at Google Scholar · View at Scopus
  25. A. N. Orekhov, “Direct anti-atherosclerotic therapy; development of natural anti-atherosclerotic drugs preventing cellular cholesterol retention,” Current Pharmaceutical Design, vol. 19, no. 33, pp. 5909–5928, 2013. View at Google Scholar
  26. A. N. Orekhov, V. V. Tertov, Kh. A. Khashimov, S. A. Kudryashov, V. N. Smirnov, and A. N. Orekhov, “Evidence of antiatherosclerotic action of verapamil from direct effects on arterial cells,” The American Journal of Cardiology, vol. 59, no. 5, pp. 495–496, 1987. View at Google Scholar
  27. A. N. Orekhov, V. V. Tertov, Kh. A. Khashimov, S. A. Kudryashov, and V. N. Smirnov, “Antiatherosclerotic effects of verapamil in primary culture of human aortic intimal cells,” Journal of Hypertension, vol. 4, supplement 6, pp. S153–S155, 1986. View at Google Scholar
  28. P. N. Hopkins, “Molecular biology of atherosclerosis,” Physiological Reviews, vol. 93, no. 3, pp. 1317–1542, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. E. Ho, K. Karimi Galougahi, C. C. Liu, R. Bhindi, and G. A. Figtree, “Biological markers of oxidative stress: applications to cardiovascular research and practice,” Redox Biology, vol. 1, no. 1, pp. 483–491, 2013. View at Publisher · View at Google Scholar
  30. J. L. Sánchez-Quesada, S. Benítez, and J. Ordóñez-Llanos, “Electronegative low-density lipoprotein,” Current Opinion in Lipidology, vol. 15, no. 3, pp. 329–335, 2004. View at Publisher · View at Google Scholar
  31. E. Sonestedt, E. Wirfält, P. Wallström et al., “High disaccharide intake associates with atherogenic lipoprotein profile,” The British Journal of Nutrition, vol. 107, no. 7, pp. 1062–1069, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Estruch, C. Bancells, L. Beloki, J. L. Sanchez-Quesada, J. Ordóñez-Llanos, and S. Benitez, “CD14 and TLR4 mediate cytokine release promoted by electronegative LDL in monocytes,” Atherosclerosis, vol. 229, no. 2, pp. 356–362, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. V. V. Tertov, V. V. Kaplun, I. A. Sobenin, E. Y. Boytsova, N. V. Bovin, and A. N. Orekhov, “Human plasma trans-sialidase causes atherogenic modification of low density lipoprotein,” Atherosclerosis, vol. 159, no. 1, pp. 103–115, 2001. View at Publisher · View at Google Scholar · View at Scopus
  34. V. V. Tertov, I. A. Sobenin, Z. A. Gabbasov, E. G. Popov, and A. N. Orekhov, “Lipoprotein aggregation as an essential condition of intracellular lipid accumulation caused by modified low density lipoproteins,” Biochemical and Biophysical Research Communications, vol. 163, no. 1, pp. 489–494, 1989. View at Google Scholar · View at Scopus
  35. P. Burchardt, J. Zurawski, B. Zuchowski et al., “Low-density lipoprotein, its susceptibility to oxidation and the role of lipoprotein-associated phospholipase A2 and carboxyl ester lipase lipases in atherosclerotic plaque formation,” Archives of Medical Science, vol. 9, no. 1, pp. 151–158, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. D. Steinberg and J. L. Witztum, “Oxidized low-density lipoprotein and atherosclerosis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 12, pp. 2311–2316, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. V. V. Tertov, V. V. Kaplun, I. A. Sobenin, and A. N. Orekhov, “Low-density lipoprotein modification occurring in human plasma possible mechanism of in vivo lipoprotein desialylation as a primary step of atherogenic modification,” Atherosclerosis, vol. 138, no. 1, pp. 183–195, 1998. View at Publisher · View at Google Scholar · View at Scopus
  38. V. V. Tertov, G. Bittolo-Bon, I. A. Sobenin, G. Cazzolato, A. N. Orekhov, and P. Avogaro, “Naturally occurring modified low density lipoproteins are similar if not identical: more electronegative and desialylated lipoprotein subfractions,” Experimental and Molecular Pathology, vol. 62, no. 3, pp. 166–172, 1995. View at Publisher · View at Google Scholar · View at Scopus
  39. W. Palinski, M. E. Rosenfeld, S. Yla-Herttuala et al., “Low density lipoprotein undergoes oxidative modification in vivo,” Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 4, pp. 1372–1376, 1989. View at Publisher · View at Google Scholar · View at Scopus
  40. A. G. Kacharava, V. V. Tertov, and A. N. Orekhov, “Autoantibodies against low density lipoprotein and atherogenic potential of blood,” Annals of Medicine, vol. 25, no. 6, pp. 551–555, 1993. View at Google Scholar · View at Scopus
  41. I. A. Sobenin, V. P. Karagodin, A. A. Melnichenko, Y. V. Bobryshev, and A. N. Orekhov, “Diagnostic and prognostic value of low density lipoprotein-containing circulating immune complexes in atherosclerosis,” Journal of Clinical Immunology, vol. 33, no. 2, pp. 489–495, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. M. S. Safarova, M. V. Ezhov, O. I. Afanasieva et al., “Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography,” Atherosclerosis Supplements, vol. 14, no. 1, pp. 93–99, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Yamamoto, M. Harada-Shiba, A. Kawaguchi, and M. Tsushima, “Apheresis technology for prevention and regression of atherosclerosis,” Therapeutic Apheresis, vol. 5, no. 4, pp. 221–225, 2001. View at Publisher · View at Google Scholar · View at Scopus